Last reviewed · How we verify
L. rhamnosus GG - Probiotic
At a glance
| Generic name | L. rhamnosus GG - Probiotic |
|---|---|
| Also known as | Culturelle Probiotic |
| Sponsor | McMaster University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Intervention of Obesity in Children With Prader-Willi Syndrome Using Prebiotics and Probiotics (NA)
- GynMDD Add-On to Supportive Psychotherapy in Mild to Moderate Depression (NA)
- Single Vs Multi-strain Probiotics for Preterm Neonates (PHASE4)
- Probiotic Mixture (L. Rhamnosus GG and L. Plantarum 299V) In Pediatric Irritable Bowel Syndrome (NA)
- COMPARISON OF ZINC AND PROBIOTICS ON NEONATES WITH INDIRECT HYPERBILIRUBINEMIA UNDERGOING PHOTOTHERAPY (PHASE2)
- Probiotic and Prebiotic Use in Early Postoperative Period of Sleeve Gastrectomy (NA)
- Effects of Vivatlac Baby on Crying Behavior of Colicky Babies (PHASE2)
- Effect of L. Rhamnosus Yoba on RTI and Other Health Outcomes Among Children (3-6 Years) in Uganda (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- L. rhamnosus GG - Probiotic CI brief — competitive landscape report
- L. rhamnosus GG - Probiotic updates RSS · CI watch RSS
- McMaster University portfolio CI